First ever European PCV2-Research Award Winners Honoured
GERMANY - Prof. Hans Nauwynck, Prof. Joaquim Segalés, Danja Wiederkehr together and Dr. Xaver Sidler are the first ever winners of the European PCV2 Research Award

Production Benefits from IIleitis Vaccine
MID WEST - Porcine ileitis, a common disease also known as Porcine Proliferative Enteropathy, is caused by the bacterium Lawsonia intracellularis. The costs of the disease can be high and have been projected to exceed US$22 per affected pig and production...

Ileitis on a High Says Scottish Census
SCOTLAND - Results from a recent survey indicate that more than 60 per cent of slaughter pigs suffer some degree of Ileitis during their lives. The findings, collected from a comprehensive blood-testing programme carried out in Scotland, provides valuable...

New Additon to Swine Team
MISSOURI – Bill Knoch has joined Boehringer Ingelheim Vetmedica as sales representativeannounced within its swine division.

PCV2 Vaccine in ample supply
US - One of the swine industry's biggest disease challenges in recent years has been the emergence of PMWS and PCV Associated diseases.

Boehringer Ingelheim Announces Swine Division Additions
US - Boehringer Ingelheim Vetmedica, Inc., (BIVI) swine division announces the following additions to its U.S. swine team.

EU PCV-2 Annual Research Award launched by Boehringer Ingelheim
GERMANY - Boehringer Ingelheim Animal Health announced the launch of the European PCV-2 Award, which recognizes excellent research proposals in the area of applied immunological PCV-2 research.

75,000 Euro's available for PCV-2 Research - Apply here!
EU - Boehringer Ingelheim Animal Health GmbH is offering a total sum of 75,000 €uro's annually for the best research proposals in the field of applied immunological PCV-2 research.

Circovirus Vaccine Receives Four-Month Duration of Immunity Approval
US - Boehringer Ingelheim Vetmedica, Inc., (BIVI) has announced that the U.S. Animal and Plant Health Inspection Service has approved a duration of immunity (DOI) claim for Ingelvac® CircoFLEX™ of at least four months for porcine circovirus...

Boehringer Ingelheim Hires Three Swine Team Members
US - Boehringer Ingelheim Vetmedica, Inc., (BIVI) swine division announces the following additions to its sales organization.

Boehringer Ingelheim Receives APHIS Approval on new Circovirus Vaccine
US - Boehringer Ingelheim Vetmedica, Inc., (BIVI) has announced that it has received approval from the U.S. Animal and Plant Health Inspection Service for a new vaccine called Ingelvac® CircoFLEX™ to protect swine against diseases caused by porcine...

Further step in generation change at Boehringer Ingelheim decided
GERMANY - Dr Heribert Johann, Chairman of the Shareholders’ Committee of Boehringer Ingelheim, will retire at the end of 2006 after more than 31 years with the Corporation.

Boehringer Ingelheim and Danish Meat Associations to fully settle vaccine case in Denmark
DENMARK - Danish pig producers have today entered into a settlement with Boehringer Ingelheim Denmark A/S in a court case concerning the vaccination of Danish pig herds with a vaccine, which is used to prevent the dreaded pig disease Porcine Reproductive...

Co-Factors Play Huge Role in Circovirus-Associated Disease
NORTH AMERICA - Porcine circovirus type 2 (PCV2) has been present in the world's pig population a long time. So why is the virus now being blamed for so many mortalities in the Midwest, the Southeast and parts of Canada?

Eastern Canada Hit Hard
CANADA - Between the fall of 2004 and the spring of 2005, finishing units in Quebec were hit hard by disease characterized by wasting, anemic pigs showing respiratory distress, diarrhea, ulcers and dermatitis nephropathy syndrome between 13-18 weeks of...

Easily Confused With Ileitis
US - Clinically, PCV2 is easily confused with ileitis. Observations in the U.S. indicate circovirus is linked to enteric effects, according to Dr. John Kolb, biologics manager for Boehringer Ingelheim Vetmedica, Inc.

Continued strong growth at Boehringer Ingelheim
COPENHAGEN - In 2006 once again Boehringer Ingelheim continues to be one of the world’s fastest growing pharmaceutical companies. As the company, based in Ingelheim am Rhein, announced, it was thanks in particular to the strong therapeutic potential of...

Ileitis Symposium during the IPVS in Copenhagen
COPENHAGEN - Boehringer Ingelheim is proud to announce the 2nd Boehringer Ingelheim IPVS Ileitis symposium during the IPVS 2006 congress in Copenhagen.

Enterisol® Ileitis approved in Australia - first live swine vaccine ever in this market
AUSTRALIA - Boehringer Ingelheim Animal Health GmbH, announced today that the Australian regulatory authorities have granted market authorization for the porcine live vaccine Enterisol® Ileitis. Enterisol® Ileitis has been approved for the active immunization...

Boehringer Donates PRRS Risk Assessment Program To Industry
US - Boehringer Ingelheim Vetmedica, Inc., last week transferred ownership of its Risk Assessment Program for porcine reproductive and respiratory syndrome (PRRS) to the American Association of swine Veterinarians (AASV).